Trials / Completed
CompletedNCT01939899
Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma
An Open-label, Multicenter, Phase 2 Study of Oral IXAZOMIB (MLN9708) in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Millennium Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the anti-tumor activity of oral Ixazomib as measured by overall response rate (ORR) in adult participants with relapsed and/or refractory follicular lymphoma (FL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IXAZOMIB | Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days. |
Timeline
- Start date
- 2013-10-31
- Primary completion
- 2016-06-01
- Completion
- 2017-03-23
- First posted
- 2013-09-11
- Last updated
- 2019-10-29
- Results posted
- 2019-10-29
Locations
14 sites across 4 countries: United States, Belgium, Canada, United Kingdom
Source: ClinicalTrials.gov record NCT01939899. Inclusion in this directory is not an endorsement.